-
Posted by
Two Blokes May 12 -
Filed in
Stock
-
7 views
Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism. The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes the near-term outlook is mixed.
